Table 1.
Selected baseline demographic and clinical characteristics of 24 patients with metastatic MITF family translocation renal cell carcinoma treated with an immune checkpoint inhibitor
| Characteristics | Number of patients | Percentage of patients |
|---|---|---|
| Sex | ||
| Male | 4 | 20 |
| Female | 20 | 80 |
| Age, years | ||
| Median | 34 | |
| Range | 3–79 | |
| ≤ 34 | 11 | 46 |
| > 34 | 13 | 54 |
| Karnofsky score | ||
| ≤ 80 | 9 | 40 |
| > 80 | 13 | 60 |
| Translocation type | ||
| TFE3 | 21 | 88 |
| TFEB | 3 | 12 |
| Common site of metastasis | ||
| Lymph nodes | 15 | 63 |
| Lung | 8 | 33 |
| Liver | 8 | 33 |
| Bone | 8 | 33 |
| Heng score | ||
| 0 (favorable) | 2 | 8 |
| 1–2 (intermediate) | 18 | 75 |
| 3–4- 5 (poor) | 4 | 17 |
| First-line therapy | ||
| Sunitinib | 15 | 63 |
| Pazopanib | 4 | 17 |
| Sorafenib | 1 | 4 |
| m-TOR inhibitor | 2 | 8 |
| High dose IL2 | 1 | 4 |